Interception

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Retrieved on: 
Thursday, December 1, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
  • Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
  • Over 80% of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer

Retrieved on: 
Thursday, November 17, 2022

This newest study underscores the robustness and validity of our previous results, by adding more biological value to the individual methylation marker regions, said Christian Hense, COO at Universal DX.

Key Points: 
  • This newest study underscores the robustness and validity of our previous results, by adding more biological value to the individual methylation marker regions, said Christian Hense, COO at Universal DX.
  • Investigating their impact on gene expression and putting these biomarkers in the context of biological pathways allows for better understanding of the behavior of early cancer.
  • Differential signal was observed between AA and NAT and CRC and adjacent normal tissue, indicating biological signal change with adenoma progression to cancer.
  • Universal DX will present its findings live at the AACR special conference on Precisions, Prevention, Early Detection, and Interception of Cancer in Austin, TX November 17-19.

Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi's AI Liquid Biopsy Platform

Retrieved on: 
Friday, November 18, 2022

BALTIMORE and PALO ALTO, Calif., Nov. 18, 2022 /PRNewswire/ -- Positive liver cancer detection data published in Cancer Discovery1 demonstrates the promise of Delfi Diagnostics' high-performance, accessible liquid biopsy platform in a new tumor type. Delfi had previously announced that it is developing a low-cost, highly sensitive blood test for lung cancer screening. The new findings, which will also be presented in Austin, Texas at AACR's Special Conference on Precision Prevention, Early Detection and Interception of Cancer, show how Delfi's platform could be applied in a second clinical context.

Key Points: 
  • Findings to be Presented at AACR Precision Prevention, Early Detection and Interception of Cancer Conference
    BALTIMORE and PALO ALTO, Calif., Nov. 18, 2022 /PRNewswire/ -- Positive liver cancer detection data published in Cancer Discovery1 demonstrates the promise of Delfi Diagnostics' high-performance, accessible liquid biopsy platform in a new tumor type.
  • Delfi had previously announced that it is developing a low-cost, highly sensitive blood test for lung cancer screening.
  • The ravages of liver cancer are underappreciated in terms of their public health impact.
  • "These data, combined with our previous promising data in lung cancer, provides an additional proof of concept for our technology platform across multiple cancer types.

Data retention privacy obligations

Retrieved on: 
Monday, October 31, 2022

Data retention privacy obligations

Key Points: 
  • Data retention privacy obligations
    The Office of the Australian Information Commissioner (OAIC) has published Privacy business resource 11: Telecommunications service providers obligations arising under the Privacy Act as a result of Part 5-1A of the TIA Act to assist telecommunications carriers and service providers to understand their key privacy obligations under the data retention scheme, which is due to commence on 13 October 2015.
  • Following commencement of that scheme, all carriers, carriage service providers and internet service providers will have obligations under the Privacy Act 1988 (Privacy Act).
  • Privacy business resource 11 outlines key obligations under the Australian Privacy Principles as contained in Schedule 1 to the Privacy Act.
  • The OAIC encourages all carriers and service providers to review the resource and consider how they will comply with their privacy obligations in relation to data collected and retained under the data retention scheme.

Major Companies in the Global Lawful Interception Market Include Utimaco, Vocal Technologies, AQSACOM, Verint, BAE Systems, SS8 Networks, & Signalogic - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022

Lawful Interception Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global lawful interception market.

Key Points: 
  • Lawful Interception Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global lawful interception market.
  • It places the market within the context of the wider lawful interception market, and compares it with other markets.
  • Key financial deals which have shaped the market in recent years are identified
    The lawful interception market section of the report gives context.
  • It compares the lawful interception market with other segments of the lawful interception market by size and growth, historic and forecast.

Global Lawful Interception Markets Report 2021-2026 - Growing Deployment of 5G Networks / Interception Activities on IP Packets / Increase in Government Investments to Track the Criminal Activities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 24, 2021

The "Global Lawful Interception Market (2021-2026) by Component, Network, Mediation Services, Interception, Network Technology, Communication Content, End-users, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lawful Interception Market (2021-2026) by Component, Network, Mediation Services, Interception, Network Technology, Communication Content, End-users, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Lawful Interception Market is estimated to be USD 3.81 Bn in 2021 and is expected to reach USD 9.2 Bn by 2026, growing at a CAGR of 19.2%.
  • Rising digitalization and advancements in communication technologies make it easier for cybercriminals to vest themselves in criminal activities and even in cyber-terrorism.
  • All these factors have been contributing effectively to the growth of the lawful interception market.